CANCER BIOPSY MARKET ANALYSIS

Cancer Biopsy Market, By Product (Instruments, Kits and Consumables, and Services), Biopsy Type (((Tissue Biopsy (Needle Biopsy (Fine Needle Aspiration (FNA) and Core Needle Biopsy (CNB)), Liquid Biopsy, and Others))), and By Application (Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer, Skin Cancer, Blood Cancer, Kidney Cancer, Liver Cancer, Pancreatic Cancer, Ovarian Cancer, and Others) By Geography (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa))-

Published In : Jun 2023
Code : CMI5930
Pages :160
Formats :
Excel and PDF
Industry : Clinical Diagnostic

Leading Companies

Companies covered:

QIAGEN, Illumina, Inc., Angle PLC, Myriad Genetics, COUNSYL, Inc., Hologic, Inc., Biocept, Inc., Thermo Fisher Scientific, Inc., Danaher, F. Hoffmann-La Roche Ltd., Epigenomics AG, BD (Becton, Dickinson and Company), and Helio Health (Laboratory for Advanced Medicine), among others.

Global Cancer Biopsy Market: Key Companies Insights

The global cancer biopsy market is highly competitive. This is attributed to the increasing burden of oncology disorders and increase in adoption of liquid biopsies, as a result, players in the market are focusing on launching novel products in the market.

Some of the key players in the global cancer biopsy market are QIAGEN, Illumina, Inc., Angle PLC, Myriad Genetics, COUNSYL, Inc., Hologic, Inc., Biocept, Inc., Thermo Fisher Scientific, Inc., Danaher, F. Hoffmann-La Roche Ltd., Epigenomics AG, BD (Becton, Dickinson and Company), and Helio Health (Laboratory for Advanced Medicine), among others.

CANCER BIOPSY MARKET ANALYSIS

Leading Companies

Cancer Biopsy Market Report Snapshots

EXISTING CLIENTELE